Phibro Animal Health Corporation surged 5% in after-hours trading after reporting stronger-than-expected fourth-quarter and full-year results, alongside upwardly revised fiscal 2027 guidance.
The Teaneck, New Jersey-based animal health company posted adjusted earnings of $0.85 per share for the quarter ended June 30, 2026, beating the $0.72 estimate by 18%. Revenue totaled $396.7 million, a 5% increase from $378.6 million in the prior-year period and above the $382.51 million consensus. Full-year net sales reached $1.52 billion, up 17% year-over-year, while adjusted earnings per share climbed 48% to $3.22.
Adjusted EBITDA rose 39% to $255 million for the fiscal year, reflecting margin expansion. Chief Executive Officer Dani Bendheim highlighted the company’s progress, citing record net sales and improved profitability.
For fiscal 2027, Phibro guided adjusted EPS to $3.41–$3.59, with a midpoint of $3.50, exceeding the $3.07 consensus. Revenue is projected at $1.55–$1.60 billion, above the $1.49 billion estimate. Guidance assumes minimal virginiamycin sales in Brazil pending regulatory approval for therapeutic use.
The company also announced plans to close its Chicago Heights manufacturing facility in summer 2027, affecting about 100 employees. Production will be consolidated into other Phibro facilities and third-party manufacturers.
